Inhibrx Inc (INBX)
34.06
-0.03
(-0.09%)
USD |
NASDAQ |
Apr 26, 16:00
34.05
-0.01
(-0.03%)
After-Hours: 20:00
Inhibrx Cash from Operations (Quarterly): -56.82M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -56.82M |
| September 30, 2023 | -54.24M |
| June 30, 2023 | -42.30M |
| March 31, 2023 | -39.94M |
| December 31, 2022 | -30.60M |
| September 30, 2022 | -30.84M |
| June 30, 2022 | -26.92M |
| March 31, 2022 | -26.94M |
| December 31, 2021 | -22.62M |
| September 30, 2021 | -13.68M |
| June 30, 2021 | -22.38M |
| Date | Value |
|---|---|
| March 31, 2021 | -21.65M |
| December 31, 2020 | -15.39M |
| September 30, 2020 | -13.88M |
| June 30, 2020 | -11.31M |
| March 31, 2020 | -7.388M |
| December 31, 2019 | -11.94M |
| September 30, 2019 | -0.773M |
| June 30, 2019 | -13.79M |
| March 31, 2019 | -5.577M |
| June 30, 2018 | -13.01M |
| March 31, 2018 | -2.114M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-56.82M
Minimum
Dec 2023
-0.773M
Maximum
Sep 2019
-24.39M
Average
-22.38M
Median
Jun 2021
Cash from Operations (Quarterly) Benchmarks
| Axonics Inc | 5.63M |
| NovaBay Pharmaceuticals Inc | -0.314M |
| Palatin Technologies Inc | -10.48M |
| iBio Inc | -4.706M |
| Theriva Biologics Inc | -6.541M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -3.442M |
| Cash from Financing (Quarterly) | 0.86M |
| Free Cash Flow | -197.90M |
| Free Cash Flow Per Share (Quarterly) | -1.114 |
| Free Cash Flow to Equity (Quarterly) | -61.51M |
| Free Cash Flow to Firm (Quarterly) | -56.74M |
| Free Cash Flow Yield | -12.33% |